ORYZON GENOMICS, S.A. from 10/09/2019 to 10/09/2019 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 10/09/2019 07:41 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon presents vafidemstat efficacy data from the REIMAGINE Phase IIa trial’s Autism Spectrum Disorder (ASD) cohort Register number: 281608